2BBBullish & Bearish
Beam Therapeutics Inc. (BEAM) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 54 out of 100.
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.
Beam Therapeutics Inc.’s current 2BB score is 54 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 66 | High |
| Momentum | 52 | Stable |
| Financial strength | 26 | Weak |
| Quality | 97 | Very Strong |
| Risk | 34 | Low |
| CEO | John Evans |
| Founded | 2017 |
| Employees | 540 |
| 52-week range | $20.23 – $38.26 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-02-22 | — | -1.2059 | — | $10.34M |
| 2026-11-02 | — | -1.1783 | — | $8.93M |
| 2026-08-11 | — | -1.1285 | — | $16.70M |
| 2026-05-07 | -0.91 | -1.1155 | $31.74M | $11.20M |